← Back to Search

Behavioral Intervention

Personalized Text Messaging for Type 2 Diabetes (REINFORCE2 Trial)

N/A
Waitlist Available
Research Sponsored by Brigham and Women's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of Type 2 Diabetes Mellitus (T2DM)
Prescribed between 1-3 daily oral medications for diabetes
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Summary

This trial will test if personalized text messages can help people with type 2 diabetes take their meds, with the goal of improving health outcomes.

Who is the study for?
This trial is for adults aged 18-84 with type 2 diabetes who have a recent HbA1c level of at least 7.5%, use a smartphone, understand English or Spanish, take 1-3 daily oral diabetes meds, and have been less than ideally consistent with their medication (PDC <0.80). It's not for those getting daily help with meds or unwilling to switch to electronic pill bottles.
What is being tested?
The study tests if personalized text messages based on reinforcement learning can improve medication adherence in type 2 diabetes patients compared to standard texts. Participants will be randomly assigned to receive either tailored messages that adapt over time or generic ones, both potentially up to daily.
What are the potential side effects?
Since the intervention involves only behavioral messaging via text and does not include medications or medical procedures, there are no direct physical side effects expected from participating in this trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with Type 2 Diabetes.
Select...
I take 1 to 3 pills daily for my diabetes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Diabetes medication adherence
Secondary study objectives
Glycemic control

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Reinforcement Learning Intervention ArmExperimental Treatment1 Intervention
Up to daily, tailored text messages.
Group II: Control ArmActive Control1 Intervention
Up to daily, untailored text messages.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Reinforcement Learning
2021
N/A
~60

Find a Location

Who is running the clinical trial?

National Institute on Aging (NIA)NIH
1,733 Previous Clinical Trials
28,054,943 Total Patients Enrolled
Brigham and Women's HospitalLead Sponsor
1,653 Previous Clinical Trials
11,490,975 Total Patients Enrolled
Boston Medical CenterOTHER
395 Previous Clinical Trials
875,469 Total Patients Enrolled

Media Library

Reinforcement Learning (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05742685 — N/A
Type 2 Diabetes Research Study Groups: Reinforcement Learning Intervention Arm, Control Arm
Type 2 Diabetes Clinical Trial 2023: Reinforcement Learning Highlights & Side Effects. Trial Name: NCT05742685 — N/A
Reinforcement Learning (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05742685 — N/A
~8 spots leftby Nov 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top